Learn more in our training program.
Join our membership network.
Attend our events and collaborate.
Add your voice to our policy matters.
Get involved in our genetic registry.
Donate to our cause.
The Latino Cancer Institute (TLCI) is a nationwide community and research network dedicated to solving the issues and burden of Latino cancer.
Cancer remains one of the leading causes of death among Hispanics/Latinos in the U.S., accounting for approximately 17% of deaths. At the same time, federal support for health equity and cancer disparities research is facing unprecedented cuts—making community-driven leadership more critical than ever.
Cancer affects Latino men and women differently, requiring targeted approaches. Among Latinas, breast cancer remains the most commonly diagnosed cancer and the leading cause of cancer death, while cervical cancer continues to pose a serious and largely preventable threat.
For Latino men, the challenges are equally urgent. Lung cancer remains the leading cause of cancer death, and Latino men are more likely to be diagnosed with prostate, colorectal, liver, and testicular cancers—often at later stages.
Our mission. The Latino Cancer Institute works to reduce the burden of cancer in Latino communities by convening expertise, amplifying community-informed research, and advocating for equitable cancer care. As public funding becomes more uncertain, philanthropic support helps ensure Latino communities are not left out of cancer research, policy discussions, or solutions. Learn more about our work.
For over 20 years, Founder Ysabel Duron has played a vital role in bringing together those dedicated to making a difference in the Latino cancer landscape. From cancer community workers and caregivers to international medical researchers and policymakers, Ysabel has forged important alliances in a field crowded with many competing interests and agendas.
It takes a savvy insider who has traveled this terrain far and wide to help the Latino cancer community at-large continue changing the landscape. TLCI offers the definitive road map.
There are currently no upcoming events.
The Latino Cancer Institute acts as a network for agencies, linking members to share knowledge and best practices. Connecting colleagues, peers and institutions is critical to The Institute’s ongoing mission to amplify and disseminate outstanding work in the cancer arena, and to support one another.
The Latino Cancer Institute provides opportunities to network, learn and collaborate with stakeholders in the cancer landscape including Latino cancer researchers.
The Latino Cancer Institute convenes leading experts, advocates, and community voices to examine critical cancer issues affecting Latino communities and to surface actionable insights. Recordings from TLCI’s recent Forums are now available—free to watch—covering cancer risks, disparities, and lived experiences across Latino women, men, children, and families. Watch Forum videos.
The Latino Cancer Institute leverages our united voice at the national table to advance Latino cancer concerns including education, services, funding, and research. Our aim is to be heard, understood and included in any proposed policy.
As a nonprofit organization, we rely on philanthropy and grants in our mission to support other agencies. Your funding allows us to continue the development of new programs and tools we can share with those making a difference in the lives of Latino cancer patients, survivors, and their caregivers.
Some cancer cells evade treatment by entering a dormant state triggered by stress hormones. ETH Zurich scientists have created a light-controlled molecular switch that selectively destroys the receptors responsible for this survival mode. In laboratory lung cancer cells, the approach woke sleeping tumor cells and could help make future cancer therapies more effective while minimizing damage to healthy tissue.
A UCLA study has identified a hidden Achilles' heel in aggressive small cell cancers that have resisted new treatments for decades. Scientists found that tumors lacking the RB gene become critically dependent on the protein E2F3 for survival. Blocking E2F3 shut down tumor growth in laboratory models, and existing FDA-approved drugs may be able to exploit this vulnerability. The discovery could pave the way for faster development of more effective therapies.
A new intranasal DNA vaccine may give the immune system an extra weapon against tuberculosis by targeting bacteria that can hide from antibiotics. In animal studies, it helped clear infections faster, reduced lung inflammation, and prevented relapse after treatment. The vaccine also enhanced the performance of drugs used against drug-resistant TB.
Could something as simple as vitamin C help support a healthier aging brain? In a study of more than 2,000 older adults in Japan, researchers found that people with lower vitamin C levels in their blood also tended to have less gray matter and weaker connections in a key brain network involved in memory, attention, and other cognitive functions.
Scientists at the University of Oxford have created a calculator that predicts a person's individual risk of serious muscle disorders from statin medications. Their analysis found that more than 98% of people who qualify for statins are at low risk for these rare complications, despite widespread concerns about side effects. The study also revealed that most eligible patients are not taking statins, potentially missing important protection against heart attacks and strokes.
A new stem-cell-inspired technique allows scientists to grow vast numbers of immune-cell progenitors that can be engineered to hunt cancer and strengthen immune responses. In animal studies, the cells fought tumors, restored immune function, and showed promise as a durable, off-the-shelf therapy platform.
Sept. 18, 25 
